MaxCyte, Inc.
MaxCyte, Inc. (Nasdaq: MXCT) develops cell-engineering technologies for biopharmaceutical companies, biotechnology companies, academic institutions and government research organizations. Its proprietary Flow Electroporation technology introduces molecules such as DNA, RNA and proteins into cells, supporting research,… From the company’s description.
Over the twelve months to Jun 30, 2026, MaxCyte, Inc. reported revenue of $31.05M, down 13.2% from a year earlier, and a net loss of $35.64M. Its operating margin was −134.6%, and operations used $22.98M in cash. In fiscal 2025, it reported revenue of $33.03M, down 14.5% from fiscal 2024, and a net loss of $44.63M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MaxCyte, Inc. does
In the company’s own words
MaxCyte, Inc. (Nasdaq: MXCT) develops cell-engineering technologies for biopharmaceutical companies, biotechnology companies, academic institutions and government research organizations. Its proprietary Flow Electroporation technology introduces molecules such as DNA, RNA and proteins into cells, supporting research, drug discovery and the development and manufacture of cell and gene therapies. The ExPERT platform comprises DTx, ATx, STx, GTx and VLx instruments, along with single-use processing assemblies and consumables, and is designed to scale from laboratory research to clinical and commercial production. Applications also include transient production of proteins, viral vectors and vaccines. MaxCyte licenses its instruments and platform to customers, including through strategic platform license agreements that can provide access to regulatory files and involve milestone and commercial sales-based payments. The company also offers gene-editing assessment services through SeQure Dx, acquired in 2025. As of December 31, 2025, MaxCyte had 91 full-time employees and 31 active strategic platform license agreements. Its website is www.maxcyte.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- ROCKVILLE, MD
- Fiscal year end
- December
- CIK
- 1287098
- SIC
- 8731
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MaxCyte, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MaxCyte, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MaxCyte, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MaxCyte, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MaxCyte, Inc.'s last four quarterly filings that the numbers alone won't show?”